Adenosine A3 receptors on human eosinophils mediate inhibition of degranulation and superoxide anion release
TL;DR: The results show that the A3 receptors on human eosinophils mediate inhibition of both degranulation and O2− release and suggest a therapeutic potential for A3 agonists in diseases such as asthma in which activated eosInophils are involved.
read more
Abstract: The role of adenosine A3 receptors on human eosinophil degranulation and superoxide anion (O2-) release was studied in vitro using the complement fragment C5a as the main stimulus and employing a number of selective agonists and antagonists. In the presence of cytochalasin B (CB), C5a induced a dose-dependent release of the granular eosinophil peroxidase (EPO), but not O2-, whereas in the absence of CB O2- , but not EPO, was released. C5a-induced EPO release was inhibited dose-dependently by the selective A3 agonist N6-(3-iodobenzyl)-5'-N-methylcarbamoyladenosine (IB-MECA) and to a lesser extent by the less-selective N6-2-(4-amino-3-iodophenyl) ethyladenosine (APNEA). The IC50 (95% CI) for IB-MECA was 6.8 microM (3.1-12.0 microM). At concentrations up to 100 microM, neither adenosine nor the selective A1 agonist N-cyclopentyladenosine (CPA) and the selective A2 agonist 2-[[2-[4-(2-carboxyethyl)phenyl]ethyl]amino]-N-ethylcarboxamidoadenosine (CGS 21680) had any significant effect. The inhibitory effect of IB-MECA was almost completely abolished by pre-treatment with 1 microM of the selective A3 antagonist 9-chloro-2-(2-furyl)-5-phenylactylamino[1,2,4]triazolo[1,5-c]quina zoline (MRS 1220), but not the selective A1 antagonist 1,3-dipropyly-8-cyclopentylxanthine (DPCPX) or the selective A2 antagonist 3,7-dimethyl-1-propargylxanthine (DMPX). IB-MECA also significantly inhibited C5a-induced O2- release with IC50 (95% CI) of 9.5 microM (4.6-13.1 microM) whereas adenosine and the A1 agonist CPA potentiated this effect at low concentrations. The potentiation appeared to be a result of their direct O2- release from these cells, probably mediated via A1 receptors. The inhibition by IB-MECA was selectively reversed by MRS 1220. These results show that the A3 receptors on human eosinophils mediate inhibition of both degranulation and O2- release and suggest a therapeutic potential for A3 agonists in diseases such as asthma in which activated eosinophils are involved.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Other Mediators of Airway Disease
Peter J. Barnes
- 01 Jan 2002
TL;DR: The detailed role of additional mediators as implicated in asthma and chronic obstructive pulmonary disease (COPD) is highlighted and the synthesis and metabolism of these mediators are emphasized.
A 3 Adenosine Receptor in the Pulmonary System
Yifat Klein,Idit Matot +1 more
- 01 Jan 2010
TL;DR: The human A3AR mediates anti-inflammatory cell responses upon its activation on these cells, via direct effect on cell migration, degranulation or the production of cytokines, however, stimulatory effects were also reported.
Patent
4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and their use
Castelhano Arlindo L,Bryan Mckibben,Witter David J +2 more
- 31 Mar 2004
TL;DR: In this paper, novel deazapurines are disclosed which are useful for the treatment of adenosine receptor stimulated diseases, such as cancer, melanoma, and AIDS.
A(3) adenosine receptor ligands: history and perspectives.
Pier Giovanni Baraldi,Barbara Cacciari,Romeo Romagnoli,Stefania Merighi,Katia Varani,Pier Andrea Borea,Giampiero Spalluto +6 more
TL;DR: Based on results, highly selective A3 adenosine receptor agonists and/or antagonists have been indicated as potential drugs for the treatment of asthma and inflammation, while highly selective agonists have been shown to possess cardioprotective effects.
Alteration of A3 adenosine receptors in human neutrophils and low frequency electromagnetic fields
Katia Varani,Stefania Gessi,Stefania Merighi,Valeria Iannotta,Elena Cattabriga,Cecilia Pancaldi,Ruggero Cadossi,Pier Andrea Borea +7 more
TL;DR: Results indicate in human neutrophils treated with PEMFs the presence of significant alterations in the A(3) adenosine receptor density and functionality.
References
•Journal Article
Nomenclature and classification of purinoceptors
Bertil B. Fredholm,Maria P. Abbracchio,Geoffrey Burnstock,J. W. Daly,T K Harden,Kenneth A. Jacobson,P Leff,Michael Williams +7 more
TL;DR: The evidence is now compelling that ATP plays important physiological and/ or pathophysiological roles in a variety of biological systems, and the presence of receptors for ADP and adenosine (presumably A2) receptors exist on platelets is compelling.
1.6K
Damage of the airway epithelium and bronchial reactivity in patients with asthma.
TL;DR: In this paper, the authors measured bronchial reactivity to inhaled histamine and prepared electron micrographs from 8 asthmatic patients who never smoked (2 females, 6 males, 18 to 62 yr of age).
1.3K
Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor.
TL;DR: The highest expression of R226 was in the testis and low-level mRNAs were also found in the lung, kidneys, heart, and some parts of the central nervous system such as cortex, striatum, and olfactory bulb, suggesting a possible role for adenosine in reproduction.
695
The eosinophil and the pathophysiology of asthma
Evangelo Frigas,Gerald J. Gleich +1 more
TL;DR: These and other findings suggest the hypothesis that the eosinophil mediates damage to the respiratory epithelium and is the prime effector cell in the pathophysiology of asthma.
633
An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils
TL;DR: The immunomagnetic method permits the efficient isolation of highly purified and functionally active eosinophil isolation after N-formyl-methionyl-leucyl-phenyl-alanine treatment.
630